TERT and glioblastoma: For example, the Oncomine v2 panel lacks evaluation of the TERT promoter, which is diagnostically critical for glioblastoma and CNS WHO grade 3 meningiomas, and it is recurrently altered other tumors, including oligodendroglioma.